Health
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase
About this update from Cytokinetics, Incorporated
[{"type":"image","alt":"Cytokinetics, Incorporated","displaySize":"","headline":null,"caption":"Cytokinetics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J0pajxHwFe95Ug.L7DMD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e","width":300,"height":131}},"lazy":false},{"type":"text","content":"Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints","length":144,"tagName":"p"},{"type":"text","content":"Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time","length":81,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM).","length":389,"tagName":"p"},{"type":"text","content":"ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to Week 36 compared to placebo in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2) (Table 1).","length":275,"tagName":"p"},{"type":"text","content":"“Patients with non-obstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease. We hope that will change with ACACIA-HCM which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with non-obstructive HCM,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “We believe that the totality and consistency of evidence favoring aficamten across multiple patient-reported and physician-assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with non-obstructive HCM.”","length":698,"tagName":...